Rivaroxaban may reduce ischaemic events post acute coronary syndrome
스크롤 이동 상태바
Rivaroxaban may reduce ischaemic events post acute coronary syndrome
기자명
메디칼라이터팀
입력 2009.06.18 00:00
수정 2009.06.18 09:28
댓글 0
Phase II results from trials of the anticoagulant rivaroxaban (Xarelto) are promising in showing that it may reduce major ischaemic events like death, MI and stroke post acute coronary syndrome. A dose-dependent increase in clinically significant bleeding occurred so ongoing trials are required to outweigh benefits associated with this risk.